The Urinary Tract Infection Therapeutic Market is estimated to be valued at US$ 9,193.23 Mn in 2023 and is expected to exhibit a CAGR of 3.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
The urinary tract infection therapeutic market includes products used for the treatment of urinary tract infections such as antibiotics. Some common antibiotics used for treating urinary tract infections include nitrofurantoin, trimethoprim-sulfamethoxazole, cefdinir, cefpodoxime, and ciprofloxacin. These antibiotics are available as capsules, tablets, and intravenous solutions depending on the severity of infection. The choice of antibiotic used is based on factors such as which part of the urinary tract is infected, type of bacteria causing infection, and resistance of the bacteria.
Market Dynamics:
One of the key drivers contributing to the growth of urinary tract infection therapeutics market is the high prevalence rate of urinary tract infections globally. For instance, according to the National Institutes of Health, 50% of women experience at least one urinary tract infection in their lifetime. Moreover, recurrent urinary tract infections affect nearly 25% of women. Rising geriatric population is also propelling the market growth as aged people are more susceptible to urinary tract infections due to weakening of the immune system. Additionally, emergence of antibiotic-resistant bacterial strains resulting from overuse of antibiotics is causing concerns and driving the need for developing novel therapeutics for treating drug resistant infections.
Segment Analysis
The global urinary tract infection therapeutic market is segmented on the basis of drug class, indication, distribution channel and region. Based on drug class, the market is segmented into quinolones, azoles and beta-lactam, among which the quinolones segment holds the largest market share owing to attributes like effectiveness against a wide range of bacteria and high bioavailability. In terms of indication, the market is categorized into complicated UTI and uncomplicated UTI, out of which, the uncomplicated UTI segment dominates due to high prevalence of the condition. By distribution channel, the market is bifurcated into hospital pharmacies and retail pharmacies & drug stores, of which the hospital pharmacies segment is the most profitable as the condition usually requires consulting a medical expert.
PEST Analysis
Political: Changes in drug approval and regulations impact the research and development activities in this market.
Economic: Stable rise in disposable incomes in developing nations drives the demand for quality healthcare and thereby supplements market growth.
Social: Increasing awareness regarding personal hygiene and early treatment of urinary tract infections favours the market expansion.
Technological: Advancements in drug delivery systems and development of novel treatment alternatives such as combination therapies support market revenue.
Key Takeaways
The Global Urinary Tract Infection Therapeutic Market Size size was valued at US$ 9193.23 Mn in 2023 and is expected to reach US$ 13,458.1 Mn by 2030, exhibiting a CAGR of 3.0% during the forecast period. The rising geriatric population which is highly susceptible to UTIs and favorable government support to research activities are fueling the market growth.
Regionally, North America captures the majority market share attributed to developed healthcare infrastructure, high awareness levels, and new product approvals in the region. However, Asia Pacific is anticipated to witness the fastest growth rate owing to growing healthcare expenditures, large patient population, and increasing focus of key players on emerging countries.
Key players operating in the urinary tract infection therapeutic market are Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., and GlaxoSmithKline PLC, among others. These players are focusing on new product launches, acquisitions, and collaborations to strengthen their market position. For instance, in 2022, GlaxoSmithKline PLC received approval from USFDA for Bexsero, a vaccine to prevent infections caused by Neisseria meningitidis serogroup B in individuals aged 10 through 25 years old.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it